Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device clinical trials

A randomized, double-blind, placebo-controlled, multicenter trial assessing the reduction of the rate of lipoprotein apheresis after treatment with pelacarsen (TQJ230) compared to placebo in patients with hyperlipoproteinemia(a) and established cardiovascular disease undergoing weekly lipoprotein apheresis in Germany

This study looks at a new medicine called pelacarsen (TQJ230) for people with high levels of a certain type of fat in their blood, called Lp(a). These people are already having a special treatment called lipoprotein apheresis. The study wants to see if pelacarsen can help reduce how often they need this treatment.